Abstract A novel cyclic peptide antibiotic, pargamicin A was isolated from the culture broth of an actinomycete strain. The producing organism, designated ML1-hF4, was identified as a member of the genus Amycolatopsis. In the course of screening for new antimicrobial substances from microorganisms, we found that an actinomycete strain isolated from a soil collected in Tokyo, Japan, produces a new cyclic peptide antibiotic, which was named pargamicin A (1, Fig. 1 ). Compound 1 showed strong antibacterial activity against MRSA and VRE.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis/faecium (VRE) are among the most problematic pathogens in hospitalacquired infections. Moreover, two clinical isolate strains of vancomycin-resistant S. aureus (VRSA) have been isolated from patients in USA since 2002 [1] . Today, only a few drugs such as linezolid [2] , quinupristin/dalfopristin [2] and daptomycin [2] are clinically used for both VRE and MRSA infections. Therefore, the development of novel drugs effective for VRE and MRSA (VRSA) is greatly desired.
In the course of screening for new antimicrobial substances from microorganisms, we found that an actinomycete strain isolated from a soil collected in Tokyo, Japan, produces a new cyclic peptide antibiotic, which was named pargamicin A (1, Fig. 1 ). Compound 1 showed strong antibacterial activity against MRSA and VRE.
In this paper, we describe the identification of the producing organism, isolation, fermentation, structure elucidation and biological activities of 1.
Materials and Methods

General
Optical rotation was measured with a Perkin-Elmer model 241 polarimeter. UV spectra were recorded with a Hitachi 557 spectrophotometer. The IR spectrum was recorded with a Horiba FT-210 Fourier transform infrared spectrometer. The 1 H-and 13 C-NMR spectra were measured with a JEOL JNM-A500 spectrometer at 24°C using TMS as an internal reference. The mass spectrum was recorded with a JEOL JMS-SX102 mass spectrometer.
Taxonomy
The pargamicin A-producing organism, strain ML1-hF4 was isolated from a soil sample collected at Shinagawa, Tokyo, Japan. Morphological, cultural and physiological properties of the strain ML1-hF4 were examined according to the methods described by SHIRLING and Gottlieb [3] , and Waksman [4] . Detailed observation of mycelial morphologies was performed with the use of a scanning electron microscope (Model S-570, Hitachi) after strain ML1-hF4 was incubated on sucrose-nitrate agar at 27°C for 12 days. Chemical analysis of the cell wall was performed using TLC according to the method of Staneck and Roberts [5] . Whole-cell sugars were determined by the methods of Lechevalier and Lechevalier [6] . Menaquinones were extracted following the method of Collins et al. [7] , and analyzed by LC-MS (model M-1200H, Hitachi) with a CAPCELL PAK AG, C 18 column (4.6 mmϫ150 mm, Shiseido Co., Ltd., Japan) using MeOH -isopropanol (2 : 1, v/v) as the mobile phase. Phospholipids and mycolic acids were analyzed by the procedures of Minnikin et al. [8, 9] . A total DNA sample of strain ML1-hF4 was prepared as reported [10] . The 16S ribosomal RNA gene (16S rDNA) was amplified by polymerase chain reaction (PCR) using genomic DNA of strain ML1-hF4 and sequenced [11] . A homology search for the most related sequences was performed using the BLAST algorithm on the DDBJ/Genebank/EMBL.
Fermentation
A slant culture of the pargamicin-producing organism was inoculated into a 500-ml baffled Erlenmeyer flask containing 110 ml of a seed medium consisting of glycerol 1.0%, dextrin 1.0%, Soytone Peptone (Difco) 0.5%, yeast extract 1.5%, (NH 4 ) 2 SO 4 1.0% and CaCO 3 1.0% in deionized water (pH 7.4 before sterilization). The culture was incubated on a rotary shaker (180 rpm) at 30°C for 3 days. A 2.5 ml aliquot of the seed culture were transferred into a 500-ml Sakaguchi flask containing 125 ml of a producing medium consisting of galactose 2.0%, dextrin 2.0%, glycerol 1.0%, Soytone Peptone (Difco) 0.5%, corn steep liquor 0.5% and CaCO 3 0.2% in deionized water. The fermentation was carried out on a reciprocal shaker (130 rpm) at 27°C for 5 days.
Analytical Procedure
The content of 1 in the fermentation broth and the various purification steps was monitored with reversed-phase HPLC and silica gel TLC. HPLC was performed with a CAPCELL PAK, AG, C 18 column (4.6ϫ150 mm, Shiseido Co., Ltd., Japan; mobile phase, CH 3 CN : H 2 Oϭ35 : 65; flow rate, 2.0 ml/minute; column temperature, 50°C; detection, UV at 238 nm). Compound 1 was eluted at 7.5 minutes. The antibiotic was detected on TLC plates with a solution of mixture of molybdophosphoric acid and sulfuric acid in 
Biological Activity
The MIC of pargamicin A were examined by serial agar dilution method using Mueller-Hinton agar (Difco) for bacteria including Enterococci and Staphylococcus aureus [12] . The MIC was observed against bacteria and yeast after incubation for 18 hours at 37°C.
Results and Discussion
Taxonomic Features of Strain ML1-hF4
Strain ML1-hF4 produced well-branched substrate mycelia. Aerial hyphae were straight or flexuous. Both substrate and aerial hyphae exhibited nocardioform fragmentation. The spore was cylindrical with a smooth surface and 0.4ϳ0.6ϫ0.8ϳ1.6 m m in size (Fig. 1) . No synnemata, sclerotia, sporangia or motile spores were observed.
The taxonomic properties of strain ML1-hF4 are shown in Table 1 . Whole-cell hydrolysates of strain ML1-hF4 contained meso-diaminopimelic acid of the cell wall and galactose and arabinose. The predominant menaquinone was MK-9(H 4 ). The phospholipid pattern was type PII: phosphatidylethanolamine was present, but neither phosphatidylcholine nor unknown glucosamine-containing phospholipids were found. Mycolic acids were absent. The aerial mycelia of strain ML1-hF4 were white on various agar media. The substrate mycelia were pale yellow to pale brown. Soluble pigments were not produced. Permissive temperature ranges for growth of the strain were 20ϳ37°C. The optimal temperature for growth of the strain ML1-hF4 was 30°C.
The partial 16S rDNA sequence (457 bp, positions 27ϳ510, Escherichia coli numbering system [13] ) of strain ML1-hF4 showed high similarity value with members of the genus Amycolatopsis, such as Amycolatopsis albidoflavus AB327251 (444/457, 97%), A. halotorelans DQ000196 (443/458, 96%), A. echigoensis AB248535 (443/459, 96%) and A. niigatensis AB248537 (441/458, 96%).
These phenotypic and genotypic properties suggested that strain ML1-hF4 belonged to the genus Amycolatopsis [14] . Therefore, the strain was identified as an Amycolatopsis sp. and designated Amycolatopsis sp. ML1-hF4. Detailed taxonomic study of strain ML1-hF4 is in progress.
Fermentation and Isolation
The fermentation broth (5.0 liters) was separated to the mycelial cake and supernatant by centrifugation. The supernatant was applied on a Diaion HP20 (Mitsubishi Chemical Co.) column (38ϫ155 mm). The column was washed with deionized water (450 ml) and 50% aq MeOH (450 ml). The active principle was eluted with 80% aq MeOH (450 ml) and 80% aq Me 2 CO (450 ml). The active solutions were collected and concentrated in vacuo to yield a brown oil (576 mg). The brown oil containing the active substance was chromatographed on a silica gel column with stepwise development comprising successive 300 ml aliquots of EtOAc : MeOH mixtures of compositions 10 : 1, 9 : 1, 4 : 1 and 2 : 1, respectively. The active fractions were collected and concentrated in vacuo to give a pale brown powder (158 mg). The active material was further purified by reversed phase HPLC developing with CH 3 CN : H 2 Oϭ35 : 65 (CAPCELL PAK C18 UG120, 4.6ϫ150 mm, Shiseido Co., Ltd. Japan, flow rate, 8.0 ml/minute). The active fractions were collected and concentrated in vacuo to give 1 (78 mg, Fig. 2 ) as colorless powder.
Structure Elucidation of Pargamicin
The physico-chemical properties of pargamicin are summarized in The connectivity between these residues was established by the key HMBC correlations illustrated in Fig. 4 Pargamicin has a unique cyclic peptide containing N-methyl-and N or C-hydroxyl-amino acids. The stereochemistry and the structures of other analogs of pargamicin will be reported later.
Biological Activity
The antimicrobial activities of 1 are shown in Table 4 . Pargamicin A (1) showed strong antimicrobial activities against Gram-positive bacteria including MRSA and VRE strains (Table 3) . Its MICs were 0.39ϳ0.78 m g/ml for susceptible S. aureus and multidrug-resistant S. aureus including MRSA, and 0.39 m g/ml for susceptible E. faecalis/faecium (nϭ2) and vancomycin resistant E. faecalis/faecium (nϭ4). However, 1 showed no activity at 100 mg/ml against pathogenic Gram-negative bacteria and yeast such as Salmonella enteritidis and Candida albicans, respectively.
Discussion
Our screening program for new antibiotics has yielded a new anti-MRSA and anti-VRE agent designated pargamicin A (1) from an Amycolatopsis sp. Compound 1 showed strong antimicrobial activities against MRSA and VRE. It is worth noting that 1 showed more potent activity against VRE than current anti-VRE drugs. Structural studies revealed that 1 is a cyclic hexapeptide antibiotic containing unusual residues including piperazic acid and Nmethyl and N-or C-hydroxyl amino acid. Compound 1 is a cyclic peptide antibiotic containing piperazic acid. This residue is an unusual amino acid that has been found previously in peptides or cyclic depsipeptides from actinomycetes but has previously only been described once as a component of an actinomycete-derived cyclic peptide. L 156373, discovered as oxtocin and vasopressin antagonist in 1989 by Pettibone D. J. et al. is the sole example from a Streptomyces [15] . While L 156373 shares structural similarities with 1, it has no anti-MRSA/VRE activities. These results indicate that 1 should be an interesting lead compound for the development of novel anti-MRSA/VRE drugs based on the new mode of action. Studies on the mode of action of 1 and the structure-activity relations are under investigation. Shigella dysenteriae JS 11910 Ͼ100 Ͼ100
Salmonella enteritidis Ͼ100 Ͼ100
Pseudomonas aeruginosa A3 Ͼ100 Ͼ100
Klebsiella pneumonie PCI 602 Ͼ100 Ͼ100
Candida albicans 3147 Ͼ100 Ͼ100
